ArticleMolecular neurobiology2025
Potential Therapeutic Effects of Astragaloside IV in Parkinson's Disease Models via Modulation of α-syn-γH2AX-STING-IFN-I Axis.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Finding a new drug to slow or reverse the progression of Parkinson's disease (PD) is a significant step forward. Astragaloside Ⅳ (AS-Ⅳ) has been shown to have neuroprotective and anti-inflammatory properties, but its therapeutic effects and mechanisms in PD remain to be determined. Unilateral injection of rotenone (ROT) into the substantia nigra pars compacta (SNpc) was used to establish an in vivo model of PD. AS-Ⅳ intraperitoneal injection (IP) (40 mg/kg once/day for 14 days) was administered 6 weeks after modeling. Behavioral assessments were conducted using the limb hanging test, rotarod test, and gastrointestinal motility evaluations. The expression and localization of alpha-synuclein (α-syn) /γH2AX/STING/IFNα/βRα were explored using western blotting and confocal laser scanning microscopy. In vitro, ROT-treated BV2 microglial cells were used to mimic PD-associated neuroinflammation, and AS-Ⅳ was added 6 h post-ROT exposure. Genetic overexpression of A53T/A30P mutant α-syn was performed to investigate α-syn aggregation and pathway activation. AS-Ⅳ treatment significantly improved motor performance, reduced gastrointestinal dysfunction, and protected against DA neuron loss. The application of AS-Ⅳ inhibited α-syn aggregation and decreased the expression of γH2AX, STING, and IFNα/βRα in vivo and in vitro. The use of a STING inhibitor (H151) or agonist (2,3-cGAMP) confirmed that the α-syn-γH2AX-STING-IFN-I axis played a critical role in PD progression. AS-Ⅳ also restored ROT-induced loss of BV2 cell viability. In ROT-based PD in vivo and in vitro models, and α-syn mutant-mediated cell models, the α-syn-γH2AX-STING-IFN-I axis was activated, and α-syn aggregation was the upstream regulatory protein of STING. AS-Ⅳ might exert therapeutic effects via the α-syn-γH2AX-STING-IFN-I axis.
Indexed as
Identifiers
41204052What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.